[CAS NO. 1323077-89-9] Enzaplatovir

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [1323077-89-9]

Catalog

HY-109004

Brand

MCE

CAS

1323077-89-9

DESCRIPTION [1323077-89-9]

Overview

MDL	-
Molecular Weight	377.40
Molecular Formula	C20H19N5O3
SMILES	O=C(C1=CON=C1C)N2[C@](CN3C4=CC=C3)(C(C=C5)=CN=C5C)N(CC2)C4=O

For research use only. We do not sell to patients.

Summary

Enzaplatovir (BTA-C585) is an orally bioavailable fusion inhibitor for respiratory syncytial virus ( RSV ) infection ^[1] .

IC50 & Target

RSV ^[1]

In Vitro

Respiratory syncytial virus (RSV)-associated lower respiratory tract infection (LRTI) imposes a substantial medical burden. Enzaplatovir is a small-molecule RSV entry inhibitor ^[1] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT02718937	Biota Pharma Europe Limited\|Vaxart	Respiratory Syncytial Virus (RSV) Infection	March 2016	Phase 2
NCT02558413	Biota Pharmaceuticals, Inc.\|Vaxart	Pharmacokinetics\|Healthy Volunteers	August 2015	Phase 1
NCT02668367	Biota Pharmaceuticals, Inc.\|Vaxart	Pharmacokinetics\|Healthy Volunteers	November 2015	Phase 1

Appearance

Solid

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : 200 mg/mL ( 529.94 mM ; Need ultrasonic)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.6497 mL	13.2485 mL	26.4971 mL
5 mM	0.5299 mL	2.6497 mL	5.2994 mL
10 mM	0.2650 mL	1.3249 mL	2.6497 mL

* Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)

Solubility: ≥ 6 mg/mL (15.90 mM); Clear solution
2.

Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

Solubility: ≥ 5 mg/mL (13.25 mM); Clear solution
3.

Add each solvent one by one: 10% DMSO >> 90% corn oil

Solubility: ≥ 5 mg/mL (13.25 mM); Clear solution

* All of the co-solvents are available by MCE.

References

[1] Eric A F Simões, et al. Past, Present and Future Approaches to the Prevention and Treatment of Respiratory Syncytial Virus Infection in Children. Infect Dis Ther. 2018 Mar;7(1):87-120.